Bioton S.A. Market Cap ($80.35 Million)
Market Cap & Net Worth: Bioton S.A. (BIO)
Bioton S.A. market cap. Bioton S.A. (WAR:BIO) has a market capitalization of $80.35 Million (zł291.94 Million) as of November 1, 2026. Listed on the WAR stock exchange, this Poland-based company holds position #19853 globally and #161 in its home market, demonstrating a -8.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bioton S.A.'s stock price zł3.40 by its total outstanding shares 85864200 (85.86 Million). Also see how efficiently does Bioton S.A. generate cash for how efficiently the company converts equity into cash flow.
Bioton S.A. Market Cap History (2015–2026)
Bioton S.A. market cap history from 2015 to 2026. Data shows change from $281.92 Million to $80.35 Million (-9.79% CAGR). Check Bioton S.A. stock quote for real-time trading data and today's change.
Bioton S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bioton S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Bioton S.A. to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.32x
Bioton S.A.'s market cap is 0.32 times its annual revenue
Latest Price to Earnings (P/E) Ratio
26.88x
Bioton S.A.'s market cap is 26.88 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $193.07 Million | $277.61 Million | -$28.57 Million | 0.70x | N/A |
| 2017 | $82.47 Million | $361.65 Million | -$7.27 Million | 0.23x | N/A |
| 2018 | $119.57 Million | $241.17 Million | $26.27 Million | 0.50x | 4.55x |
| 2019 | $89.80 Million | $202.03 Million | -$126.69 Million | 0.44x | N/A |
| 2020 | $102.32 Million | $221.79 Million | $33.92 Million | 0.46x | 3.02x |
| 2021 | $98.90 Million | $163.03 Million | $2.88 Million | 0.61x | 34.32x |
| 2022 | $79.64 Million | $233.16 Million | $1.42 Million | 0.34x | 56.04x |
| 2023 | $84.36 Million | $181.64 Million | $2.27 Million | 0.46x | 37.08x |
| 2024 | $68.18 Million | $207.76 Million | -$15.66 Million | 0.33x | N/A |
| 2025 | $91.22 Million | $282.52 Million | $3.39 Million | 0.32x | 26.88x |
Competitor Companies of BIO by Market Capitalization
Companies near Bioton S.A. in the global market cap rankings as of November 1, 2026. Also see BIO asset base for a full breakdown of the balance sheet.
Key companies related to Bioton S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Bioton S.A. (2015–2026)
Market capitalization of Bioton S.A. from 2015 to today. Between 2015 and today, Bioton S.A.'s market cap moved from $281.92 Million to $ 80.35 Million, with a yearly change of -9.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | zł80.35 Million | -11.92% |
| 2025 | zł91.22 Million | +33.80% |
| 2024 | zł68.18 Million | -19.19% |
| 2023 | zł84.36 Million | +5.93% |
| 2022 | zł79.64 Million | -19.47% |
| 2021 | zł98.90 Million | -3.35% |
| 2020 | zł102.32 Million | +13.95% |
| 2019 | zł89.80 Million | -24.90% |
| 2018 | zł119.57 Million | +44.99% |
| 2017 | zł82.47 Million | -57.28% |
| 2016 | zł193.07 Million | -31.52% |
| 2015 | zł281.92 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Bioton S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $80.35 Million USD |
| MoneyControl | $80.35 Million USD |
| MarketWatch | $80.35 Million USD |
| marketcap.company | $80.35 Million USD |
| Reuters | $80.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bioton S.A.
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; oral diabetic drugs; strips for measuring sugar in blood, as well as Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes m… Read more